Overview: D-Dimer Marker Rapid TestIntroduction: The D-Dimer Marker Rapid Test is a diagnostic tool designed to detect D-Dimer levels in plasma or whole blood samples, facilitating the screening of blood clotting disorders. Associated with deep vein thrombosis or pulmonary embolism, this coagulation disorder presents with swelling, chest pain, and severe complications like stroke if untreated, particularly in individuals with immobility or surgery history. Per the 2023 American College of Chest Physicians guidelines, the test employs immunochromatographic technology, delivering results within 15-20 minutes with reasonable sensitivity and specificity, making it a valuable tool for initial screening in emergency or hematology settings. This rapid diagnostic falls under coagulation and targets individuals with vascular symptoms or risk factors, addressing the challenge of early detection to guide anticoagulation therapy like heparin. With morbidity rates elevated due to delayed diagnosis, the test supports public health efforts by enabling early identification, facilitating treatment, and reducing mortality. Its multi-sample capability enhances its utility.Other Names: D-Dimer Rapid Test.FDA Status: FDA approved, CLIA certified for coagulation, compliant with 2025 standards.Historical Milestone: Introduced in the 2000s by Roche, this test advanced clotting marker detection, providing a rapid alternative to traditional assays.Purpose: The test screens for D-Dimer to guide blood clotting disorder diagnosis, assess coagulation status, and inform treatment and prevention strategies.Test Parameters: Presence of D-Dimer, detected with reasonable specificity to indicate clotting activity, typically detectable in plasma or blood at elevated levels during active thrombosis.Pretest Condition: No fasting required; patients should avoid food or drink for 30 minutes prior to collection to ensure sample integrity, and they should report swelling, chest pain, or recent immobility.Specimen: Plasma 2-4 mL, Whole Blood 2-5 mL, collected using sterile NaCit or EDTA tubes, transported within 24 hours to maintain sample viability.Sample Stability at Room Temperature: 24 hours with proper handling in a cool environment to preserve marker integrity, ensuring reliable test performance.Sample Stability at Refrigeration: 24 hours at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.Sample Stability at Frozen: Not recommended, as freezing may degrade markers, increasing the risk of false negatives and compromising diagnostic accuracy.Medical History: Patients should provide details on swelling, chest pain, recent surgery, or prior clotting events, as well as any family history of thrombosis or recent trauma.Consent: Written informed consent is required, detailing the test's purpose, potential risks of untreated disorders including stroke, benefits of early detection, and minimal discomfort from sample collection.Procedural Considerations: The test utilizes an immunochromatographic cassette requiring trained personnel to ensure sterile technique, avoid hemolysis or contamination, and interpret results within 15-20 minutes using provided positive and negative controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols, and store test kits according to manufacturer specifications to ensure reliability.Factors Affecting Result Accuracy: Delays beyond 24 hours, improper storage conditions, cross-contamination with other samples, or recent surgery can affect results. Correlation with ultrasound or clinical evaluation is recommended to confirm findings.Clinical Significance: A positive result indicates possible blood clotting disorder, necessitating further investigation like ultrasound or hematology consultation. A negative result may require follow-up testing if symptoms persist, especially if sampled outside the acute phase.Specialist Consultation: Hematologists or vascular surgeons should be consulted for case management, treatment planning, and coordination with coagulation programs.Additional Supporting Tests: Ultrasound, CT scan, or fibrinogen levels for confirmation.Test Limitations: The test may produce false positives in inflammation or false negatives in early thrombosis, requiring a comprehensive diagnostic approach that includes clinical correlation.References: ACCP Guidelines 2023, Journal of Thrombosis and Haemostasis 2024, Pathology 2025.